• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Figure 25 is a forest plot depicting our meta-analysis on improvement in total/global scores for dementia by drug and dose. One placebo controlled trial of aripiprazole evaluated three different doses, ranging from 2mg to 10mg. Only the 10mg dose reported a statistically significant effect size, at 0.28. The pooled result of these three dose groups for aripiprazole was a statistically significant standardized effect size of 0.17. Two placebo controlled trials of olanzapine evaluated its use at 6 differing dose levels. Doses ranged from 1mg to 15mg. One 5mg olanzapine group had a statistically significant standardized effect size of 0.44. The overall pooled result for the differing olanzapine dose groups was a statistically significant standardized effect size of 0.16. One placebo controlled trial of quetiapine reported two dose groups (100mg & 200mg), neither of which reported a statistically significant effect. One placebo controlled trial of risperidone reported on three dose groups ranging from 0.5mg to 2mg. The 1mg and 2mg group had a statistically significant standardized effect size of 0.32 and 0.49, respectively. The overall pooled result for risperidone was a statistically significant standardized effect size of 0.32.

Figure 25Dementia: PCTs—with dose comparisons—total/global scores

From: Results

Cover of Off-Label Use of Atypical Antipsychotics: An Update
Off-Label Use of Atypical Antipsychotics: An Update [Internet].
Comparative Effectiveness Reviews, No. 43.
Maglione M, Maher AR, Hu J, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.